RT Journal Article
SR Electronic
T1 Integrated Genomic Analyses Identify High-Risk Factors and Actionable Targets in T-Cell Acute Lymphoblastic Leukemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.17.21260159
DO 10.1101/2021.07.17.21260159
A1 Zhu, Haichuan
A1 Dong, Bingjie
A1 Zhang, Yingchi
A1 Wang, Mei
A1 Rao, Jianan
A1 Cui, Bowen
A1 Liu, Yu
A1 Jiang, Qian
A1 Wang, Weitao
A1 Yang, Lu
A1 Yu, Anqi
A1 Li, Zongru
A1 Liu, Chao
A1 Zhang, Leping
A1 Huang, Xiaojun
A1 Zhu, Xiaofan
A1 Wu, Hong
YR 2021
UL http://medrxiv.org/content/early/2021/07/20/2021.07.17.21260159.abstract
AB T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy often associated with poor outcomes. To identify high-risk factors and potential actionable targets for T-ALL, we perform integrated genomic and transcriptomic analyses on samples from 165 Chinese pediatric and adult T-ALL patients, of whom 85% have outcome information. The genomic mutation landscape of this Chinese cohort is very similar to the Western cohort published previously, except that the rate of NOTCH1 mutations is significant lower in the Chinese T-ALL patients. Among 47 recurrently mutated genes in 7 functional categories, we identify RAS pathway and PTEN mutations as poor survival factors for non-TAL and TAL subtypes, respectively. Mutations in the PI3K pathway are mutually exclusive with mutations in the RAS and NOTCH1 pathways as well as transcription factors. Further analysis demonstrates that approximately 43% of the high-risk patients harbor at least one potential actionable alteration identified in this study, and T-ALLs with RAS pathway mutations are hypersensitive to MEKi in vitro and in vivo. Thus, our integrated genomic analyses not only systematically identify high-risk factors but suggest that these high-risk factors are promising targets for T-ALL therapies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00707083; ChiCTR-IPR-14005706;Funding StatementThis project was supported by the National Natural Science Foundation of China (81602254 for L.Y).This work was also supported by the Peking-Tsinghua Center for Life sciences and Beijing Advanced Innovation Center for Genomics at Peking University to HW.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients gave written informed consent for treatments and sample collections. The collection of samples and clinical information were approved by the Ethics Committee of Hematology Hospital, Chinese Academy of Medical Sciences and the Ethics Committee of the Peking University People's Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw sequence data reported in this paper have been deposited in the Genome Sequence Archive in National Genomics Data Center, China National Center for Bioinformation / Beijing Institute of Genomics, Chinese Academy of Sciences, under accession number HRA000122 that are publicly accessible at https://bigd.big.ac.cn/gsa.